Registrar Corp Registrar Corp LinkedIn Registrar Corp Twitter Registrar Corp Facebook Registrar Corp Google+ Registrar Corp Youtube Channel Registrar Corp FDA News Blog
HomeDrugsU.S. FDA Active Pharmaceutical Ingredients (API)API Examples › U.S. FDA Regulations: Enalaprilat

U.S. FDA Requirements: Enalaprilat

Pharmaceutical / Drug Definition : Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; inactivates bradykinin and prostaglandins. Also increases plasma renin and potassium levels and reduces aldosterone levels, resulting in systemic vasodilation.

Registrar Corp assists Enalaprilat companies with:

  • FDA Registration Enalaprilat
  • FDA Listing Enalaprilat
  • FDA Label Requirements and Exceptions Enalaprilat
  • FDA Import Information Enalaprilat
  • FDA Detentions Enalaprilat (Enalaprilat Entry Refusal)
  • General U.S. Food and Drug Administration Guidelines for:
       - Manufacturers Enalaprilat (Enalaprilat Suppliers)
       - Processors Enalaprilat
       - Repackers Enalaprilat
       - Relabelers Enalaprilat
       - Exporters Enalaprilat
       - Importers Enalaprilat
For more information about Enalaprilat, simply click below:




Live Help

 
U.S. FDA Regulations:

U.S. FDA Regulation: 21 C.F.R. Part 207


Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.
Home | About Us | News | Resources | Exhibitions | Seminars | Associations | Careers | Sitemap | Terms of Use © 2014 Registrar Corp
 
Food and Beverages | Drugs | Cosmetics | Medical Devices | Radiation-Emitting Electronic Devices | Color Additives | Tobacco